|
[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424．
|
|
[2]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132．
|
|
[3] GARRETT WS.Cancer and the microbiota[J].Science,2015,348(6230):80-86．
|
|
[4] ARTHUR JC,GHARAIBEH RZ,MHLBAUER M,et al.Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer[J].Nat Commun,2014,5:4724．
|
|
[5] BOLEIJ A,HECHENBLEIKNER EM,GOODWIN AC,et al.The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients[J].Clin Infect Dis,2015,60(2):208-215．
|
|
[6]GUERRA L,GUIDI R,FRISAN T.Do bacterial genotoxins contribute to chronic inflammation,genomic instability and tumor progression?[J].FEBS J,2011,278(23):4577-4588．
|
|
[7]XU X,HE J,XUE J,et al.Oral cavity contains distinct niches with dynamic microbial communities[J].Environ Microbiol,2015,17(3):699-710．
|
|
[8] HAN YW,FARDINI Y,CHEN C,et al.Term stillbirth caused by oral Fusobacterium nucleatum[J].Obstet Gynecol,2010,115(2 Pt2):442-445．
|
|
[9] VEGA-VILLA K,PLUTA R,LONSER R,et al.Quantitative systems pharmacology model of no metabolome and methemoglobin following long-term infusion of sodium nitrite in humans[J].CPT Pharmacometrics Syst Pharmacol,2013,2:e60．
|
|
[10] OHTANI N,KAWADA N.Role of the gut-liver axis in liver inflammation,fibrosis,and cancer:A special focus on the gut microbiota relationship[J].Hepatol Commun,2019,3(4):456-470．
|
|
[11] STALEY C,WEINGARDEN AR,KHORUTS A,et al.Interaction of gut microbiota with bile acid metabolism and its influence on disease states[J].Appl Microbiol Biotechnol,2017,101(1):47-64．
|
|
[12] PETERSON LW,ARTIS D.Intestinal epithelial cells:Regulators of barrier function and immune homeostasis[J].Nat Rev Immunol,2014,14(3):141-153．
|
|
[13] PONZIANI FR,BHOORI S,CASTELLI C,et al.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J].Hepatology,2019,69(1):107-120．
|
|
[14] JAISWAL G,DEO V,BHONGADE M,et al.Serum alkaline phosphatase:A potential marker in the progression of periodontal disease in cirrhosis patients[J].Quintessence Int,2011,42(4):345-348．
|
|
[15] LU H,REN Z,LI A,et al.Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma[J].Sci Rep,2016,6:33142．
|
|
[16]HAN P,SUN D,YANG J.Interaction between periodontitis and liver diseases[J].Biomed Rep,2016,5(3):267-276．
|
|
[17]WANG Z,REN Z,CHEN Y,et al.Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection:A randomized controlled study[J].Clin Cancer Res,2018,24(9):2074-2081．
|
|
[18]ZHU PL,YIN C,FENG JL.Progress in comprehensive treatment of primary liver cancer[J].J Clin Hepatol,2015,31(6):965-968.(in Chinese)祝普利，尹超，冯建龙．原发性肝癌综合治疗进展[J]．临床肝胆病杂志，2015,31(6):965-968．
|
|
[19] LI L,ZHANG J,LIU X,et al.Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma:Ameta-analysis[J].J Gastroenterol Hepatol,2012,27(1):51-58．
|
|
[20]HUANG J,YAN L,CHENG Z,et al.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria[J].Ann Surg,2010,252(6):903-912．
|
|
[21] Bureau of Medical Administration,National Health Commission of the People's Republic of China.Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J].J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292．
|
|
[22]ZHU AX,FINN RS,EDELINE J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):A non-randomised,open-label phase2 trial[J].Lancet Oncol,2018,19(7):940-952．
|
|
[23] JACKSON R,PSARELLI EE,BERHANE S,et al.Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer:A meta-analysis of randomized phase III trials[J].J Clin Oncol,2017,35(6):622-628．
|
|
[24]ATARASHI K,SUDA W,LUO C,et al.Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation[J].Science,2017,358(6361):359-365．
|
|
[25]LINS L,BITTENCOURT PL,EVANGELISTA MA,et al.Oral health profile of cirrhotic patients awaiting liver transplantation in the Brazilian Northeast[J].Transplant Proc,2011,43(4):1319-1321．
|
|
[26] YONEDA M,NAKA S,NAKANO K,et al.Involvement of a periodontal pathogen,Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease[J].BMC Gastroenterol,2012,12:16．
|
|
[27]CHEN B,YAN FH.Non-surgical therapy in advanced periodontitis[J].Chin J Practical Stomatology,2016,9(4):197-201.(in Chinese)陈斌，闫福华．重度牙周炎非手术治疗[J]．中国实用口腔科杂志，2016,9(4):197-201．
|
|
[28]OKUSHIN K,TSUTSUMI T,IKEUCHI K,et al.Helicobacter pylori infection and liver diseases:Epidemiology and insights into pathogenesis[J].World J Gastroenterol,2018,24(32):3617-3625．
|
|
[29]WIJARNPREECHA K,THONGPRAYOON C,PANJAWATANAN P,et al.Helicobacter pylori and risk of nonalcoholic fatty liver disease:A systematic review and Meta-analysis[J].J Clin Gastroenterol,2018,52(5):386-391．
|
|
[30] CHANG B,SANG L,WANG Y,et al.The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury[J].BMC Gastroenterol,2013,13:151．
|
|
[31]KUMAR M,VERMA V,NAGPAL R,et al.Effect of probiotic fermented milk and chlorophyllin on gene expressions and genotoxicity during AFB1-induced hepatocellular carcinoma[J].Gene,2011,490(1-2):54-59．
|
|
[32]FERRERE G,WRZOSEK L,CAILLEUX F,et al.Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice[J].J Hepatol,2017,66(4):806-815．
|
|
[33]ZONG DW,GUO CY,CHENG HT,et al.Influence of lactulose on interventional therapy for HCC patients with hepatocirrhosis and hypersplenism[J].Asian Pac J Trop Med,2016,9(2):193-196．
|
|
[34]KELLY CR,KAHN S,KASHYAP P,et al.Update on fecal microbiota transplantation 2015:Indications,methodologies,mechanisms,and outlook[J].Gastroenterology,2015,149(1):223-237．
|
|
[35] BAJAJ JS,KASSAM Z,FAGAN A,et al.Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:A randomized clinical trial[J].Hepatology,2017,66(6):1727-1738．
|
|
[36] WEINGARDEN AR,DOSA PI,DEWINTER E,et al.Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control clostridium difficile germination and growth[J].PLo S One,2016,11(1):e0147210．
|
|
[37]ZHOU C,SUN PF,YIN JY,et al.Evolution of clinical treatment in inflammatory bowel diseases by fecal microbiota transplantation[J].JShanghai Jiaotong Uni(Med Sci),2020,40(2):267-270.(in Chinese)周铖，孙鹏飞，尹继瑶，等．粪菌移植治疗炎症性肠病的研究进展[J]．上海交通大学学报(医学版)，2020,40(2):267-270．
|
|
[38]PENG PL,ZHOU XY.Risk factors and prognosis of esophagogastric variceal bleeding in liver cirrhosis[J].J Clin Med Pract,2016,20(9):171-173.(in Chinese)彭湃澜，周翔禹．肝硬化食管胃底静脉曲张破裂出血的危险因素及预后分析[J]．实用临床医药杂志，2016,20(9):171-173．
|
|
[39]LI N,ZHAO YM,CHEN ZY,et al.Dynamic effects of antibioticinduced intestinal dysbacteriosis on intestinal mucosa barrier and liver function[J].Chin J Anim Nutrition,2019,31(3):1278-1287.(in Chinese)李娜，赵玉民，陈正元，等．抗生素诱导肠道菌群失调对肠黏膜屏障和肝脏功能的动态影响[J]．动物营养学报，2019,31(3):1278-1287．
|
|
[40]XU D,GAO J,GILLILLAND M 3rd,et al.Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats[J].Gastroenterology,2014,146(2):484-496.e4．
|
|
[41] CALANNI F,RENZULLI C,BARBANTI M,et al.Rifaximin:Beyond the traditional antibiotic activity[J].J Antibiot(Tokyo),2014,67(9):667-670．
|
|
[42] YU LX,SCHWABE RF.The gut microbiome and liver cancer:Mechanisms and clinical translation[J].Nat Rev Gastroenterol Hepatol,2017,14(9):527-539．
|
|
[43] WANG Y,CAI J,ZENG X,et al.Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling[J].BMC Cancer,2015,15:821．
|
|
[44] FULDE M,SOMMER F,CHASSAING B,et al.Neonatal selection by Toll-like receptor 5 influences long-term gut microbiota composition[J].Nature,2018,560(7719):489-493．
|
|
[45] INGERSOLL MA,ALBERT ML.From infection to immunotherapy:Host immune responses to bacteria at the bladder mucosa[J].Mucosal Immunol,2013,6(6):1041-1053.
|
DownLoad: